PanGen Biotech (222110.KQ) Osake Kurssi

PanGen Biotech, Inc. engages in the development of biopharmaceutical products. The company is headquartered in Suwon, Gyeonggi-Do and currently employs 73 full-time employees. The company went IPO on 2016-03-11. The firm mainly provides contract services for the manufacture of bio pharmaceuticals, bio pharmaceuticals development technology transfer services for the manufacture of Chinese hamster ovary (CHO) cell lines and the process of products and gains royalty from the services. The firm also provides reagents which are used for the development of bio pharmaceuticals. In addition the Company is also engaged in the development of bio pharmaceuticals such as Biosimilar EPO, Recombinant Factor VIII and Biosimilar G-CSF. The firm provides its services within domestic market and to overseas markets such as China, India, Mexico, America and Europe.